U.S. FDA approves expanded use of J&J’s cancer cell therapy

(Reuters) – The U.S. Food and Drug Administration on Friday allowed the expanded use of Johnson & Johnson and Legend Biotech’s Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.

(Reporting by Disha Mishra in Bengaluru; Editing by William Mallard)